Abstract
The immune response to factor VIII and the development of inhibitory antibodies is a complex multi-factorial process involving a variety of immune regulatory genes and cells, several of which have the potential to determine risk. A better understanding of the mechanisms involved will increase the likelihood of development of new therapeutic options for patients with hemophilia. This review summarizes genetic and non-genetic risk factors currently under evaluation, and the potential modulative effect of the von Willebrand factor on factor VIII immuno- and antigenicity. In addition, the role of T-regulatory cells in the pathogenicity of inhibitors will be discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 36-42 |
| Number of pages | 7 |
| Journal | Haemophilia |
| Volume | 14 |
| Issue number | SUPPL. 3 |
| DOIs | |
| State | Published - Jul 2008 |
Keywords
- Factor VIII
- Haemophilia
- Inhibitors
- Risk factors
- T-regulatory cells
- Von Willebrand factor